Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
2006 2
2007 2
2008 5
2009 8
2010 7
2011 9
2012 13
2013 5
2014 16
2015 15
2016 13
2017 9
2018 9
2019 12
2020 15
2021 17
2022 20
2023 10
2024 18
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

188 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial.
Heerspink HJL, Agarwal R, Bakris GL, Cherney DZI, Lam CSP, Neuen BL, Sarafidis PA, Tuttle KR, Wanner C, Brinker MD, Dizayee S, Kolkhof P, Schloemer P, Vesterinen P, Perkovic V; FIND-CKD investigators. Heerspink HJL, et al. Nephrol Dial Transplant. 2024 Jun 11:gfae132. doi: 10.1093/ndt/gfae132. Online ahead of print. Nephrol Dial Transplant. 2024. PMID: 38858818
Immune cells in experimental acute kidney injury.
Jang HR, Rabb H. Jang HR, et al. Nat Rev Nephrol. 2015 Feb;11(2):88-101. doi: 10.1038/nrneph.2014.180. Epub 2014 Oct 21. Nat Rev Nephrol. 2015. PMID: 25331787 Review.
Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: results of the multicenter KMMWP2201 study.
Lee JH, Choi J, Min CK, Park SS, Jo JC, Lee YJ, Kim JS, Eom HS, Jung J, Moon JH, Cho HJ, Lee MW, Yoon SS, Byun JM, Lee JH, Lee JJ, Jung SH, Shin HJ, Kim DY, Yi JH, Lee SS, Do YR, Yoon DH, Cho H, Lee WS, Lee HS, Uhm J, Kim HJ, Jang HR, Kim SH, Kim K. Lee JH, et al. Among authors: jang hr. Haematologica. 2024 Nov 1;109(11):3681-3692. doi: 10.3324/haematol.2024.285534. Haematologica. 2024. PMID: 38841794 Free PMC article.
Role of T cells in ischemic acute kidney injury and repair.
Lee K, Jang HR. Lee K, et al. Among authors: jang hr. Korean J Intern Med. 2022 May;37(3):534-550. doi: 10.3904/kjim.2021.526. Epub 2022 Apr 28. Korean J Intern Med. 2022. PMID: 35508946 Free PMC article. Review.
188 results